James M. Cleary - Researcher Profile

Publications

2 shown

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

2021 The Lancet 2580 citations

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly , Jaffer A. Ajani , Jarosław Kużdżał +24 more

Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among ...

2021 New England Journal of Medicine 1584 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,164
Institution: Dana-Farber Cancer Institute

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-7213-3951

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.